Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up).
Adult
Aged
Aged, 80 and over
Bevacizumab
/ therapeutic use
Carboplatin
/ therapeutic use
Chemotherapy, Adjuvant
Fallopian Tube Neoplasms
/ drug therapy
Female
Fertility Preservation
France
Humans
Hyperthermia, Induced
Ovarian Neoplasms
/ drug therapy
Paclitaxel
/ therapeutic use
Peritoneal Neoplasms
/ drug therapy
Chemotherapy
Guidelines
Ovarian cancer
Primary peritoneal cancer
Surgery
Tubal cancer
Journal
Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
03
03
2019
accepted:
19
03
2019
pubmed:
3
4
2019
medline:
27
12
2019
entrez:
3
4
2019
Statut:
ppublish
Résumé
Adjuvant chemotherapy by carboplatin and paclitaxel is recommended for all high-grade ovarian and tubal cancers (FIGO stages I-IIA) (grade A). After primary surgery is complete, 6 cycles of intravenous chemotherapy (grade A) are recommended, or a discussion with the patient about intraperitoneal chemotherapy, according to her risk-benefit ratio. After complete interval surgery for FIGO stage III, hyperthermic intraperitoneal chemotherapy (HIPEC) can be proposed, in accordance with the modalities of the OV-HIPEC trial (grade B). In cases of postoperative tumor residue or in FIGO stage IV tumors, chemotherapy associated with bevacizumab is recommended (grade A).
Identifiants
pubmed: 30936025
pii: S2468-7847(19)30144-8
doi: 10.1016/j.jogoh.2019.03.018
pii:
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-386Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.